8HVA
Crystal structure of EGFR_TMX in complex with covalently bound compound 14
Summary for 8HVA
Entry DOI | 10.2210/pdb8hva/pdb |
Descriptor | Epidermal growth factor receptor, ~{N}-[6-(1-methylindol-3-yl)pyrimidin-4-yl]prop-2-enamide (2 entities in total) |
Functional Keywords | epidermal growth factor receptor kinase, covalent fragments, mutant egfr, anti-cancer, transferase |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 37811.64 |
Authors | Takahashi, M.,Dokurno, P. (deposition date: 2022-12-26, release date: 2023-12-13, Last modification date: 2024-04-03) |
Primary citation | Kuki, N.,Walmsley, D.L.,Kanai, K.,Takechi, S.,Yoshida, M.,Murakami, R.,Takano, K.,Tominaga, Y.,Takahashi, M.,Ito, S.,Nakao, N.,Angove, H.,Baker, L.M.,Carter, E.,Dokurno, P.,Le Strat, L.,Macias, A.T.,Molyneaux, C.A.,Murray, J.B.,Surgenor, A.E.,Hamada, T.,Hubbard, R.E. A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase. Rsc Med Chem, 14:2731-2737, 2023 Cited by PubMed: 38107172DOI: 10.1039/d3md00439b PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.77 Å) |
Structure validation
Download full validation report